Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme

Boehringer IngelheimBoehringer Ingelheim has signed a licence agreement with Evec, Inc., Japan, for one of its fully-human therapeutic antibody programmes. Based on the agreement, Boehringer Ingelheim will obtain worldwide exclusive development and commercialisation rights for the complete programme. In return, Evec expects to receive an upfront payment and milestone payments depending on development phases from Boehringer Ingelheim totalling up to EUR 55 million, as well as royalty payments associated with potential product sales. Further financial details have not been disclosed.

Prof. Kenzo Takada, Chairman of Evec said "We are excited to enter into this collaboration with Boehringer Ingelheim, a world recognised player in the biotechnology arena. This agreement marks a significant milestone in the development of Evec. Evec is one of the first Japanese bio venture companies which has concluded a license agreement with a western multinational pharmaceutical company. We believe that this will encourage furthermore the research and development of Japanese bio venture companies."

Dr. Andreas Barner, Vice-Chairman of the Board Corporate Division Pharma Research, Development and Medicine at Boehringer Ingelheim said "We are impressed by Evec's technology of generating fully-human antibodies and are delighted to be one of the first western multinational pharmaceutical companies to enter into a license agreement with a Japanese bio venture company. As a research-driven pharmaceutical company, Boehringer Ingelheim is committed to discovering and developing products which represent high therapeutic value. This collaboration has the potential to answer the patients' and physicians' need for new treatments that are both safe and efficacious."

About Evec
Evec is a bio venture company having its head office in Sapporo, Japan, established in 2003, spun off from Hokkaido University. Evec is specialised in development of a wide spectrum of human monoclonal antibodies in multiple therapeutic areas, such as cancer, inflammatory diseases and infectious diseases by an Epstein-Barr Virus Transformation Method.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

For further information, please visit http://www.boehringer-ingelheim.com.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...